Kawasaki, Japan

Mitsuhiro Uchida



Average Co-Inventor Count = 5.5

ph-index = 1


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mitsuhiro Uchida: Innovator in Pharmaceutical Composition

Introduction

Mitsuhiro Uchida is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing therapeutic agents for various diseases. With a total of 2 patents, his work focuses on innovative solutions for allergic and inflammatory conditions.

Latest Patents

Uchida's latest patents include a pharmaceutical composition aimed at treating allergic ophthalmic diseases and allergic nasal diseases. This composition comprises a tricyclic triazolobenzazepine derivative, specifically 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine. The invention is designed to provide strong prophylactic and therapeutic effects with minimal side effects, making it suitable for topical applications. Another significant patent focuses on a method for treating inflammatory bowel diseases. This method involves administering a therapeutically effective amount of the same triazolobenzazepine derivative or its prodrug, which has shown effectiveness even in severe cases resistant to conventional treatments.

Career Highlights

Mitsuhiro Uchida is currently associated with Meiji Seika Kaisha, Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for patients suffering from various conditions.

Collaborations

Uchida collaborates with esteemed colleagues such as Takashi Shishikura and Yukari Hoshina, contributing to a dynamic research environment that fosters innovation.

Conclusion

Mitsuhiro Uchida's contributions to pharmaceutical inventions highlight his commitment to improving healthcare through innovative solutions. His patents reflect a deep understanding of complex medical challenges and a dedication to developing effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…